ClinicalTrials.gg
CompletedNCT03772158Updated Dec 1, 2021

Cetirizine Chewable Bioequivalence and Food Effect Study

A Phase 1 interventional study of Cetirizine 10mg and Cetirizine 10 mg in Allergy, sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-01.

Sponsored by Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division (formerly part of Johnson & Johnson) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 86 studies in Hypersensitivity with a site in Canada — 8 open to participants now, 12 under way, 1 of them phase 3. Hypersensitivity · Canada.

Enrollment
48th of 71
40 · median 64
Started
2018
with 5 others
Phase 1
10 of 86
1 open now
Registered
59th of 86
by date

Among the 86 studies in Hypersensitivity with a site in Canada, this one is the 48th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2018, is one of 10 in phase 1, and was the 59th registered.

Hypersensitivity

1,058 studies on the registry are indexed under Hypersensitivity; 152 are open to participants now.

Browse Hypersensitivity studies →

Open to participants now

8 of the 86 studies in Hypersensitivity with a site in Canada are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 101 Hypersensitivity studies recruiting now, 37 (37%) set no upper age limit and 52 (51%) stop at 75 or younger; 56 take children under 18; 37 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Hypersensitivity with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to determine and compare the amount of study drug that gets into your blood after the administration of each of the three formulations of cetirizine under different conditions. Another objective of this study is to evaluate the effect of food on the amount of study drug that gets into your blood after the administration of the investigational formulation. Other objectives of this study are to determine the sensory experience and ease of swallowing the investigational formulation, as well as to determine the safety of test and reference formulations of cetirizine.

Read the detailed description

The purpose of this study is to establish bioequivalence of a cetirizine 10 mg chewable tablet manufactured at Johnson \& Johnson Consumer Inc. (McNeil LLC) with two commercially marketed cetirizine 10 mg immediate release (IR) tablets (ZYRTEC®, US reference) and (Australian/EU reference), establish bioequivalence between the two commercial products (ZYRTEC®, US reference and REACTINE®, Australian/EU reference), and to evaluate the effect of food on bioavailability of the cetirizine 10 mg chewable tablet compared to the bioavailability of cetirizine 10 mg chewable tablet administrated with water only. In addition, subject's sensory experience and ease of swallowing of the test product will be assessed.

03

Conditions studied

  • Allergy

Browse trials for

Keywords

  • Bioequivalence study
  • Healthy volunteers
  • Cetirizine
  • Tablet
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male or female subject between the ages of 18 and 55 years, inclusive. Health is defined as the absence of abnormalities as judged by the Investigator on the basis of a detailed medical history, physical examination, blood pressure, pulse rate measurements, 12-lead (ECG), as well as clinical laboratory tests. The responsible Investigator may request additional investigations or analyses if necessary.
  2. Non- or ex-tobacco user, being defined as someone who completely stopped smoking or using any form of tobacco or nicotine-containing product for at least 6 months before screening visit of this study.
  3. For females: state (i.e. at least 1 year without menses without an alternative medical condition prior to the first study drug administration) or premenopausal /perimenopausal state with an effective means of (as defined in Section 10.5.5).
  4. For males: No pregnant or lactating spouse or partner at screening and willingness to utilize an acceptable form of birth control with spouse or any potential partner during the study.
  5. (BMI) ≥ 18.5 and ≤ 30 kg/m2 with a total body weight >50 kg.
  6. A personally signed and dated document, indicating that the subject has been informed of all pertinent aspects of the study.
  7. Is able to comprehend the requirements of the study (based upon clinical site personnel's assessment) and is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified within the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Use of prescription or non-prescription medications within 5 half-lives before the first IP administration unless these are or occasional use of other medications approved by the Investigator.
  2. Use of any vitamins, dietary and herbal supplements within seven days before first dose of study drug.
  3. History of any allergy or (e.g. skin reaction, asthma, angioedema) to cetirizine or any of the formulations.
  4. If female: is pregnant, has a positive pregnancy test at screening or prior to the first study drug administration, or is planning to become pregnant during the duration of the study, and/or is breast-feeding.
  5. Has a history of gastrointestinal surgery other than appendectomy.
  6. Has hypertension, fluid retention, or heart disease either by history or by the medically qualified Investigator's medical judgment.
  7. Currently suffering from asthma or has a medically significant history of asthma in the opinion of the investigator.
  8. Has renal or hepatic impairment; according to the medically qualified Investigator discretion.
  9. Was treated with an product within 28 days or within a period less than 5 times the drug's half-life, whichever is longer, preceding the first dose of study drug.
  10. Preplanned surgical procedures during the study period as this may interfere with the conduct of the study.
  11. History of alcoholism or substance abuse, as judged by the Investigator, within the past 6 months preceding this study.
  12. Consumed alcohol beverage(s) within 48 hours preceding the first dose of study drug.
  13. History of rare hereditary problems of galactose and/or lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
  14. Any history of tuberculosis.
  15. Donation or loss of blood within 28 days prior to the first treatment visit if the estimated lost blood volume equaled or exceeded 50 mL.
  16. Donation or loss of blood within 56 days prior to the first treatment visit if the estimated lost blood volume equaled or exceeded 500 mL.
  17. Has any acute or chronic medical or psychiatric condition(s) that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the medically qualified Investigator, would make the subject inappropriate for entry into this study.
  18. Relationship to persons involved directly in the conduct of the study (i.e., principal Investigator, sub-Investigators, study coordinators, other study personnel, employees or contractors of the sponsor or Johnson \& Johnson subsidiaries, and the family of each).
  19. Has any clinically important abnormal value for serum chemistry, hematology, or urinalysis at screening. Laboratory values will generally be within the normal ranges, although minor deviations in tests (except those explicitly specified in the inclusion criteria) that are not considered clinically important by the Investigator are acceptable.
  20. Has a positive test for (HIV) 1 and 2 antibodies, surface antigen (HBsAg), or antibodies (anti-HCV).
  21. Has a positive test for alcohol or drugs of abuse at screening or prior to the first study drug administration.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Treatment A

    Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.

    Drug: Cetirizine 10mg

  • Experimental
    Treatment B

    Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast without water. Subjects will be instructed to chew the tablet completely before swallowing.

    Drug: Cetirizine 10mg

  • Experimental
    Treatment C

    Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and 30 minutes after the start of the standard high-fat breakfast and followed with 240 mL ambient water. Subjects will be instructed to chew the tablet completely before swallowing.

    Drug: Cetirizine 10mg

  • Active comparator
    Treatment D

    Single dose of currently marketed US 10 mg cetirizine as immediate release tablet (ZYRTEC®), administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.

    Drug: Cetirizine 10 mg

  • Active comparator
    Treatment E

    Single dose of currently marketed EU/Australian 10 mg cetirizine film coated tablet (REACTINE®) administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.

    Drug: Cetirizine 10 mg

Interventions

06

What researchers measure

Primary outcomes

  1. The maximum observed plasma concentration (Cmax) of cetirizine

    The maximum observed plasma concentration.

    Time frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.

  2. The area under the plasma concentration versus time curves to the last measurable concentration (AUCt)

    Area under the plasma concentration versus time curve from start of drug administration until last measurable concentration.

    Time frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.

Secondary outcomes

  1. Area under the plasma concentration versus time curve extrapolated to infinity

    Area under the plasma concentration-time curve extrapolated to infinity.

    Time frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.

  2. The time point at which the maximum concentration of cetirizine is observed (Tmax).

    The time point at which the maximum concentration of cetirizine occurs.

    Time frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.

  3. The terminal elimination half-life (T1/2) of cetirizine in plasma

    The time it takes for the cetirizine plasma concentration to fall to half of its original value.

    Time frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.

  4. The terminal elimination rate constant (lambda z) for cetirizine in plasma.

    The rate at which the drug is removed from the body system.

    Time frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.

  5. To assess subject's sensory experience and ease of swallowing of the test product

    A questionaire with 5 product sensory questions for study subjects to answer.

    Time frame: Assessed one minute after dosing, and preferably completed within 15 minutes of dosing for treatments A, B and C

  6. Number of patients with adverse events.

    An adverse event is any untoward medical occurrence in a subject after they have signed an informed consent for a trial involving an investigational product.

    Time frame: Approximately 3 months. From signed informed consent until 30 days after last treatment administration.

  7. The extrapolated part of the area under the plasma concentration versus time curve of cetirizine

    The area under the plasma concentration versus time curve from 12 hours after start of drug administration until 48 hours after start of drug administration.

    Time frame: Extrapolated from 12 hours after start of drug administration until 48 hours

07

Study locations

1 site
  • Algorithme (An altascience Company)
    Mount-Royal, Quebec H3P 3P1, Canada
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Feb 2019, 1 month.

Of 26 phase 1 interventional studies under Hypersensitivity, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 1 month is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2018
First posted
Dec 11, 2018
StartActual
Dec 11, 2018
Primary completionActual
Feb 3, 2019
CompletionActual
Feb 3, 2019
Last update
Dec 1, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03772158
Responsible party
Sponsor
First posted
Dec 11, 2018
Start date
Dec 11, 2018
Primary completion
Feb 3, 2019
Completion
Feb 3, 2019
Last update
Dec 1, 2021

Study contacts

Eric Sicard, MD
principal investigator · Algorithme Pharma Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cetirizine

Start the discussion